Non-viral vector formulations comprise typically complexes of nucleic acids with cationic polymers or lipids. However, for in vivo applications cationic formulations suffer from problems of poor tissue penetration, nonspecific binding to cells, interaction with serum proteins and cell adhesion molecules and can lead to inflammatory responses. Anionic formulations may provide a solution to these problems but they have not been developed to the same extent as cationic formulations due to difficulties of nucleic acid packaging and poor transfection efficiency. We have developed novel PEGylated, anionic nanocomplexes containing cationic targeting peptides that act as a bridge between PEGylated anionic liposomes and plasmid DNA. At optimized ratios, the components self-assemble into anionic nanocomplexes with a high packaging efficiency of plasmid DNA. Anionic PEGylated nanocomplexes were resistant to aggregation in serum and transfected cells with a far higher degree of receptor-targeted specificity than their homologous non-PEGylated anionic and cationic counterparts. Gadolinium-labeled, anionic nanoparticles, administered directly to the brain by convection-enhanced delivery displayed improved tissue penetration and dispersal as well as more widespread cellular transfection than cationic formulations. Anionic PEGylated nanocomplexes have widespread potential for in vivo gene therapy due to their targeted transfection efficiency and ability to penetrate tissues.
Introduction
There is great interest in developing nanocomplex formulations for gene delivery in vivo and for therapeutic applications as alternatives to viral vectors, due to their ability to package a wide range of nucleic acids, their low immunogenicity which allows repeated administration and their potential for chemical modification of vector components to optimize performance [1, 2] . Non-viral vectors for gene or siRNA delivery usually comprise formulations of cationic polymers or liposomes that self-assemble electrostatically on mixing with nucleic acids at optimized ratios to form cationic nanocomplexes that are often very effective as in vitro transfection agents [3] [4] [5] [6] but often display poor transfection efficiency in vivo due to their aggregation in serum and to non-specific, charge-mediated binding to anionic cell surfaces and extracellular adhesion molecules [7] [8] [9] . Stealth coatings, of nanocomplexes, for example by PEGylation, can enhance serum stability and minimize nonspecific interactions but usually reduce transfection efficiencies [10, 11] .
An alternative approach is to formulate anionic nanocomplexes that offer the advantages of better targeting specificity, lower cytotoxicity and less interaction with serum components when compared to cationic formulations [12] [13] [14] . However, the use of anionic nanocomplexes has proven problematic due to the inherent problem of achieving selfassembly with anionic vector components and nucleic acids of the same charge [15] . Anionic nanocomplexes also display poor transfection efficiency due to charge repulsion at the anionic cell surface and consequently poor cell binding and uptake. Strategies developed to overcome these challenges include using cationic agents such as Ca 2+ cations [14, [16] [17] [18] [19] or protamine [20] [21] [22] to act as an electrostatic bridge between anionic lipids and nucleic acids, the use of anionic reagents such as polyglutamate to coat cationic nanoparticles with an anionic shell [23, 24] or by formulating nanoparticles with pH-tunable lipids [25] . These anionic formulations and strategies have all shown promise for in vitro and in vivo delivery of DNA and siRNA indicating their potential for non-viral genetic therapies.
We have previously described a cationic receptor-targeted nanocomplex (RTN), comprising a mixture of cationic liposomes (L), a sixteen lysine peptide with a cyclic seven amino acid targeting domain (P) and plasmid DNA (D) which have achieved efficient in vivo gene delivery in the airway epithelium [26, 27] , tumors [28] [29] [30] and vascular tissues [31, 32] . Furthermore, we recently have described anionic nanocomplexes that comprised a peptide with a neurotensin receptortargeting motif and an anionic liposome (1:1 formulation of DOPG: DOPE) which showed targeted transfection in vitro and displayed much better distribution in rat brain than homologous cationic nanocomplexes administered by CED [33] . In this anionic nanocomplex we proposed that the peptide provides a cationic bridge between anionic liposomes and nucleic acids while also providing targeting properties via the receptorbinding peptide ligand.
The peptide ligand YGLPHKF in peptide Y was identified by biopanning a phage peptide library and closely resembles part of a targeting protein expressed by the intracellular pathogen Legionella pneumophila [31, 34] although the identity of the receptor is unknown [35] . However, we have demonstrated that this peptide mediates targeted delivery of siRNA in cationic nanocomplexes to cells of neuronal origin [34, 36] . In this study we have adapted this formulation to create anionic nanocomplexes by substituting cationic liposomes with anionic liposomes and adjusting the ratio of peptide and liposome components appropriately. In particular we have explored in vitro the effects of PEGylation on the biophysical and transfection properties of the anionic RTNs. In vivo, we have compared anionic and cationic PEGylated RTNs for dispersal and transfection in rat brain administered by convection-enhanced delivery (CED), a method that can achieve widespread dispersion of therapeutics from a single administration [37] [38] [39] [40] [41] [42] [43] .
Materials and methods

Materials
All lipids used in this study are shown in Supplementary Table 1. 1,2-dioleoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (DOPG), 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (DOPE-Rhodamine), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DPPE-PEG2000), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DOPE-PEG2000) and DOTMA/ DOPE (1:1 molar ratio) were purchased from Avanti Polar Lipids (Alabaster, Alabama, USA). GdDOTA(GAC 12 ) 2 was provided by Dr Botta (Alessandria, Italy) [44] . Peptide Y (K 16 GACYGLPHKFCG; net charge + 18), ligand YL (YGLPHKF; net charge + 2) and ligand YSL (YKHPGFL; net charge + 2) were synthesized by ChinaPeptides (Shanghai, China), while the non-targeting peptides PS (K 16 GACH PPMSKLCG; net charge +18) and peptide K 16 (KKKKKKKKKKKKKKKK; net charge + 16) were synthesized by Alta Biosciences (Birmingham, UK). The plasmid pCI-Luc consists of the luciferase gene from pGL3 (Invitrogen, Paisley, UK) subcloned into pCI (Promega, Southampton, UK). The plasmid pEGFP-N1 (4.7 kb) containing the gene GFP was obtained from Clontech (Basingstoke, UK). The oligonucleotide primers and standards for qRT-PCR were provided by qStandard (Middlesex, UK) and were as follows: eGFP: forward primer 5′-CTTCAAGATCCGCC ACAACAT-3′ and reverse primer 5′-GGTGCTCAGGTAGTGGTTGTC-3′; Rpl13: forward primer 5′-CCCTACAGTTAGATACCACACCAA-3′ and reverse primer 5′-GATACCAGCCACCCTGAGC-3′; Beta actin: forward primer 5′-ACGGTCAGGTCATCACTATCG-3′ and reverse primer 5′-AGCC ACCAATCCACACAGA-3′; Sdha: forward primer 5′-TGGACCTTGTCGTC TTTGG-3′ and reverse primer 5′-TTTGCCTTAATCGGAGGAAC-3′.
Liposome formulation
Lipids were dissolved in chloroform at 10 mg/mL then a lipid film was produced in a rotary evaporator by slowly evaporating the chloroform. Lipids were rehydrated with sterile, distilled water while constantly rotated overnight, and then sonicated in a water bath to reduce their size. was also formulated consisting of DOTMA:DOPE:DOPE-PEG2000: DOPE-Rhodamine:GdDOTA(GAC 12 ) 2 at a molar ratio of 39.5:39.5: 5:1:15 mol%, respectively. A = anionic, P = PEGylated, C = cationic, R = rhodamine and G = gadolinium.
Nanoparticle formulation
Two methods of formulating anionic nanocomplexes were evaluated. In both, nanocomplexes were prepared in water at a range of molar charge ratios of L to D while the peptide P to D molar charge ratio was maintained constant at 3: 
In vitro transfections
The murine neuroblastoma cell line Neuro-2A (ATCC, Teddington, UK), and the rat neuroblastoma cell lines B104 (ICLC, Genova, Italy) and B103 (AddexBio, San Diego, USA) were maintained in Dulbecco's Modified Eagle Medium, 1% non-essential amino acids, 1 mM sodium pyruvate and 10% FCS (Invitrogen, Paisley, UK). The human bronchial epithelial cells 16HBE14o − were provided by D. Gruenert (San Francisco, CA, USA) and were cultured in Eagle's Minimal Essential Medium with HEPES modification (Sigma-Aldrich, Poole, UK), 10% FCS and 2 mM L-glutamine. All cells were maintained at 37°C in a humidified atmosphere in 5% carbon dioxide. per well 24 h prior to transfection. The cells were pre-incubated with free ligands YL or YSL for 90 min prior to the addition of nanocomplexes at a final concentration of 100 μM. The media was then replaced with 200 μL of nanocomplexes per well containing 0.25 μg of GFP plasmid DNA that also contained free ligands YL or YSL at a final concentration of 100 μM. Plates were centrifuged at 1500 rpm for 5 min (400 ×g) and incubated for 4 h at 37°C, then the medium was replaced by the full growth medium without any ligands and incubated for a further 48 h. They were then prepared for flow cytometry analysis as above.
Particle size and charge measurements
Nanocomplexes were prepared as above and diluted with distilled water to a final volume of 1 mL and a concentration of 5 μg/mL DNA. They were then analyzed for size and charge (ζ potential) using a Malvern Nano ZS (Malvern, UK). The data were then processed by software provided by the manufacturer, DTS version 5.03. All formulations had a polydispersity index (PDI) of less than 0.3.
Turbidity assay
The turbidity of nanocomplex suspension in different serum concentrations (0-50% v/v) was determined from absorbance at 500 nm on a FLUOstar Optima spectrophotometer with a corresponding amount of serum alone as a reference [46] . Nanocomplexes were formed as described above with 1 μg DNA in a volume of 200 μL, incubated at 37°C and analyzed at regular time points over a 30 min period. Relative turbidity was determined by dividing the sample absorbance by the time zero value in water.
PicoGreen fluorescence quenching experiments
Briefly, 0.2 μg DNA was mixed with PicoGreen reagent (1:150) (Invitrogen, Paisley, UK) at room temperature in TE buffer and the DNA/PicoGreen mixture was then formulated into nanocomplexes with anionic liposome and cationic peptide as described above. Fluorescence was analyzed using a fluorescence plate reader, FLUOstar Optima (BMG Labtech, Aylesbury, UK).
In nanocomplex dissociation assays, heparin sulfate (Sigma-Aldrich, Poole, UK) was added to the PicoGreen-labeled nanocomplexes in a range of concentrations (0.05-2 U/mL). In each experiment, naked DNA stained with PicoGreen was used to normalize the PicoGreen signal detected from the nanocomplexes.
Transmission electron microscopy (TEM)
Prior to use, 300-mesh copper grid coated with a Formvar/carbon support film (Agar Scientific, Essex, UK) were "glow discharged" in an Emitech K350G system (Quorum Technologies, Essex, UK) for 15 s at 30 mA (positive polarity). The anionic nanocomplexes were prepared in water as described above then applied onto a grid and after 5 s dried by blotting with filter paper. The sample was then negatively stained with 1% uranyl acetate for 2-3 s, before blotting with filter paper and air-drying. Imaging was performed with a Philips CM120 BioTwin Transmission Electron Microscope and operated at an accelerating voltage of 120 kV. Images were captured using an AMT 5MP digital TEM camera (Deben UK Limited, Bury St. Edmunds, Suffolk, UK).
Cell proliferation assay
Cell viability was assessed in 96-well plates using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega, Southampton, UK). Neuro-2A cells were seeded and transfected with anionic and cationic nanocomplexes as above, then, after 24 h, the media were substituted for growth media containing 20 μL of CellTiter 96 Aqueous One Solution reagent. Finally, after incubation for 2 h, absorbance at 490 nm was measured on a FLUOstar Optima spectrophotometer (BMG Labtech, Aylesbury, UK). Cell viability for each complex was expressed as a percentage of the viability of control cells.
In vivo CED procedures
All in vivo studies were performed in accordance with the University of Bristol animal care policies and with the authority of appropriate UK Home Office licenses. Adult male Wistar rats (Charles River, Margate, UK, 225 to 275 g) were anesthetized and placed in a small animal stereotaxic frame (Stoelting, Illinois, USA). All CED procedures were performed using a custom-made catheter with an outer diameter of 0.22 mm and inner diameter of 0.15 mm, composed of fused silica with a laser cut tip as described previously [43] . A total volume of 5 μL of anionic and cationic PEGylated nanoparticles incorporating Gadolinium and Rhodamine (190 ng eGFP/μL) for the striatum and 2.5 μL for the corpus callosum was delivered at an infusion rate of 2.5 μL/min. The Gadolinium dose delivered here is less than 4.5 μg, which is far less than the 50% lethal dose in rodents when the Gadolinium is chelated at 1-2 mg/kg or 100-200 mg/kg for the free ion [47] . Rats were culled 48 h following CED. For immunohistochemical analysis (IHC), animals were transcardially perfused with 4% paraformaldehyde. Brains were removed and placed in 4% paraformaldehyde for 24 h, then cryoprotected in 30% sucrose in order to be processed for histology. For qRT-PCR, brains were explanted and rapidly frozen at −80°C until required.
MRI
MRI measurements were performed on a 9.4 T VNMRS horizontal bore scanner (Varian Inc. Palo Alto, CA) using a 59/26 Rapid quadrature volume coil. Fixed rat brains were imaged using a T 1 -weighted gradient echo 3D sequence (TR = 17 ms, TE = 4 ms, FA = 52 o , 40 μm isotropic resolution, Ave = 6). Distribution volumes were measured by segmenting the hyperintensities caused by the gadolinium containing nanoparticles using Amira (Visage Imaging Inc., San Diego, CA, USA).
Histological assessment and cell staining
Rat brains were cut into 35 μm thick coronal sections using a Leica CM1850 cryostat (Leica Microsystems, Wetzlar, Germany) at −20°C. For fluorescent immunohistochemistry, fixed sections were mounted on gelatine-subbed slides. Once dry, the sections were washed with PBS for 5 min × 3. Sections were blocked in PBS plus 0.1% triton-x-100 containing 10% normal donkey serum (Sigma-Aldrich, Poole, UK) for 1 h at RT. They were then washed with 0.1% triton-x-100 in PBS for 5 min. Following washing, sections were incubated in the following primary antibodies: mouse anti-NeuN (1:300; Merck Millipore, MA, USA), rabbit anti-GFP (1:200; Merck Millipore, MA, USA). The next day, the primary antibody was removed and sections were washed with 0.1% triton-x-100 in PBS for 5 min × 3. Sections were incubated with donkey anti-Mouse Cy3 or donkey anti-rabbit Cy3 (1:300; Jackson Laboratories, Sacramento, CA, USA) and DAPI (1:200 of 1 mg/mL; Sigma-Aldrich, Poole, UK) at RT for 2 h in the dark and then washed with PBS for 5 min × 3. Sections were mounted in Fluorsave™ Reagent (Calbiochem®, Merck Millipore, Billerica, MA, USA) before viewing. Images were captured using the Stereo Investigator platform (MicroBrightField Bioscience, Williston, VT, USA) with a Leica DM5500 microscope (Leica Microsystems, Germany) and digital camera (Microbrightfield Bioscience, Williston, VT, USA). Some slides were visualized by confocal microscopy on a Carl Zeiss LSM710 laser scanning microscope system (Jena, Germany) at a magnification of ×400.
qRT-PCR
Rat brains (n = 3 per formulation) were collected in RNAlater (Invitrogen, Paisley, UK) and total RNA was extracted from rat brain using the RNeasy kit according to the manufacturer's instructions (Qiagen, Crawley, UK). RNA was checked for integrity using the Agilent 2100 Bioanalyzer (Wokingham, UK). All RNA samples had a RNA integrity number (RIN) of more than 9 indicating high quality RNA. Prior to reverse transcription, each sample underwent DNase treatment (Invitrogen, Paisley, UK) to eliminate any potential genomic DNA contamination. First-strand DNA was synthesized from 1 μg of DNasetreated RNA, using random hexamers and Superscript II reverse transcriptase (Invitrogen, Paisley, UK) in a 1 h reaction at 37°C. eGFP, rat Succinate dehydrogenase complex subunit A (Sdha), rat Ribosomal protein L13 (Rpl13) and rat beta actin mRNA levels were then quantified by SYBR Green qRT-PCR using a an ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Warrington, UK). The qRT-PCR assay conditions were: stage 1, 50°C for 2 min; stage 2, 95°C for 10 min; stage 3, 95°C for 15 s, then 60°C for 1 min and repeated 40 times. Amplification efficiency was 101% (eGFP), 102% (Rpl13), 102% (beta actin) and 103% (Sdha). Copy numbers for eGFP and the three housekeeping genes were derived from standard curves constructed of purified PCR products generated for each specific primer pair ranging from 10 7 to 10 1 copies for eGFP, Rpl13, beta actin and Sdha. Copy numbers of eGFP were normalized against the geometric mean of Rpl13 and beta actin, which were the most stable genes.
Statistical analysis
Data presented in this study are expressed as the mean ± standard deviation and were analyzed using a two-tailed, unpaired Student t-test or one-way ANOVA and Bonferroni post-hoc analysis where applicable. Probability values p b 0.05 were marked with *, p b 0.01 were marked with ** and p b 0.001 were marked with ***.
Results
Development and characterization of anionic nanoparticles
LDP (Method 1) or PDL (Method 2) nanocomplexes were formulated at anionic liposome:DNA (L:D) molar charge ratios from 5:1 to 1:1. Zeta potential analysis showed that LDP and PDL nanocomplexes became strongly anionic when the L:D molar charge ratio was 3.5:1 or greater with no significant size or charge differences (Fig. 1A and B) .
PicoGreen fluorescence assays (Fig. 1S-A) showed that PDL formulations quenched fluorescence better than LDP formulations at the 5:3:1 molar charge ratio (37% quenching for LDP vs. 61% for PDL; p b 0.01) but there was no difference at the 4:3:1 ratio. Luciferase transfection efficiency comparisons in B104 and 16HBE14o− cells (Fig. 1S-B and C, respectively) showed that the PDL order of mixing was substantially better than LDP at all molar charge ratios. Therefore, based on packaging and transfection efficiencies, the PDL method of mixing was used thereafter for all anionic nanocomplexes.
Anionic liposomes (DOPG/DOPE) were then prepared with PEGylated lipids incorporated at 5% molar ratios and these liposomes were used to prepare the anionic PEGylated nanocomplexes PDL AP 1, containing the DPPE-PEG2000 liposome, and PDL AP 2 containing DOPE-PEG2000. The PEGylated nanocomplexes were both prepared at molar charge ratios of (Fig. 1C) ). The stability of nanocomplexes in 50% mouse serum was assessed where the turbidity of both PEGylated and non-PEGylated, anionic PDL nanocomplexes was less than half that of the cationic LPD formulation (Fig. 1D) .
The ability of anionic nanocomplexes to package DNA efficiently and to dissociate following heparin challenge in order to release intact DNA was then assessed. PicoGreen-labeled DNA was formulated into cationic LPD and anionic PDL, PEGylated and non-PEGylated nanocomplexes at 4:3:1 molar charge ratios. Packaging was inferred from quenching of fluorescence compared to free DNA as 100%. Non-PEGylated PDL A at 65% quenching, packaged less well than cationic LPD at 85% quenching, although PEGylation improved packaging in anionic formulations with both PDL AP 1 and PDL AP 2 also quenching DNA fluorescence by 80% (Fig. 2) . On the other hand, PDL A was the least sensitive formulation to heparin with fluorescence increasing only to 48.8%, even in the presence of 2 U/mL heparin, whereas cationic LPD only required 0.4 U/mL heparin to achieve 50% dissociation. PEGylation of anionic nanocomplexes greatly increased their sensitivity to heparin, achieving 50% dissociation at 0.14 U/mL heparin for PDL AP 1 and 0.32 U/mL of heparin for PDL AP 2 nanocomplexes (Fig. 2) .
Anionic PDL nanoparticle formulations were further characterized by negative staining transmission electron microscopy (TEM) to determine shape and morphology. Most nanocomplexes were spheres but with some rods, while PDL AP 2 also showed some 'doughnut' structures (Fig. 3) . The majority of the spherical particles for each formulation were in the range determined by particle size analysis with no obvious differences between formulations.
Enhanced targeted cell transfection efficiency and viability of anionic PDLs
Anionic PDL formulations were then compared with cationic formulations for cytotoxicity and targeted transfection efficiency in three neuroblastoma cell lines, mouse Neuro-2a and rat B103 and B104. In MTS toxicity assays of transfected Neuro-2A cells (Fig. 4A ) all three anionic formulations were less toxic than cationic LPD (p b 0.01). In Neuro-2A cells (Fig. 4B) The same trends were observed in B103 cells (Fig. 4C ) and B104 cells (Fig. 4D) where the targeted transfection efficiency and specificity of anionic PDL AP 2 was again significantly better than that of cationic LPD (p b 0.001). PDL AP 2 with peptide Y was about two-fold better than the scrambled PS formulation (p b 0.05) although both anionic and cationic formulations were significantly improved over non-targeting K 16 formulations. In B104 cells (Fig. 4D) Fig. 4E ). In addition, targeted transfection specificity was again more evident with PDL AP 2 than LPD when comparing with K 16 and PS-containing formulations (Fig. 4E) . The specificity of gene delivery by peptide Y was further demonstrated in competition experiments using excess free ligand YL (i.e. only the targeting motif of peptide Y) or excess free scrambled ligand YSL (i.e. only a scrambled motif). GFP transfection following peptide Y-mediated gene delivery was 44-fold and 8-fold reduced (p b 0.001 for both) when the gene transfer was performed in the presence of free ligand YL for PDL AP 2 and LPD nanocomplexes, respectively, whereas no significant difference was observed in the presence of free ligand YSL (Fig. 4F) . There was no effect of ligand YL or ligand YSL on peptide PS-mediated gene transfer. Reduction in reporter gene transfection was also observed when the competition experiments were performed for luciferase expression in the presence of YL ligand (approximately 12-fold and 4-fold for PDL AP 2 and LPD, respectively; p b 0.001 for both), whereas no effect was observed in the presence of YSL (Fig. 2S) . Fluorescent microscopy images also provided evidence of the high transfection efficiency of PDL AP 2 anionic nanoparticles (Fig. 5 ).
In vivo administration by CED of anionic PDLs demonstrated significant brain distribution and transgene expression
Targeted, anionic and cationic, PEGylated formulations were prepared with liposomes labeled with fluorescent rhodamine and gadolinium, an MRI contrast agent (Table 1) . Formulations containing GFP were administered to rat brains by CED into the corpus callosum and the striatum then analyzed at 48 h for distribution by MRI. Analysis by MRI (Fig. 6A) and 3D reconstructions (Fig. 6B) Histological analysis of brain sections (Figs. 6D and 3S ) also suggested better distribution of the anionic rather than cationic nanoparticles but was not quantified. Rat brain sections (Fig. 6E) showed that the rhodamine-labeled nanoparticles expressed GFP within the striatum as well as the cortex, where transfection occurred due to nanoparticles refluxed up the catheter tract on withdrawal of the cannula. Confirmation of GFP transgene expression was achieved by quantitative real time polymerase chain reaction (qRT-PCR) using samples of total RNA (Fig. 6F ) from two regions of the brain (corpus callosum and striatum). Highest expression levels were achieved by cationic formulation Cat PDL AP 2 especially in the striatum, followed by the anionic formulation Ani PDL AP 2, with no statistical differences among the groups.
Discussion
Many of the limitations of synthetic nanoparticle formulations in vivo, such as poor tissue specificity, toxicity and rapid clearance from the circulation, relate to their cationic surface charges. Stealth coatings such as PEGylation overcome some of these problems but often lead to reduced transfection efficiency [11] . For these reasons, neutral and anionic nanocomplex formulations have gained traction in the field in recent years although the level of research remains far below that of cationic formulations. One of the first such approaches involved a formulation of anionic liposomes and cationic protamine with DNA, targeted to tumor cells by folate [48] and various derivatives of this formulation have been developed in recent years [21, 22, [49] [50] [51] . Other effective approaches of preparing anionic nanocomplexes involve the use of electrostatic, anionic coating agents such as hyaluronan, polyglutamate and chondroitin sulfate applied to a cationic core nanoparticle [52] [53] [54] [55] . Such approaches have enabled the production of highly anionic nanoparticles that display comparable levels of transfection to cationic formulations but with advantages of greater specificity and lower cytotoxicity. Anionic DNA-delivery formulations have shown promising evidence of improved efficacy, biodistribution and reduced toxicity compared to cationic formulations when administered systemically for targeting of tumors [23, 48, 53, 56] . Anionic formulations have also been described for siRNA transfection with similarly promising results [16, 17, 24, 57, 58] . There is therefore a need for more research into the potential of anionic formulations to optimize their design, formulation and applications.
We are developing a platform of anionic, targeted nanocomplex formulations comprising a mixture of peptide ligands and anionic liposomes that self-assemble into anionic nanocomplexes with DNA at optimized ratios of components and order of mixing. Our first such formulation displayed far superior distribution in rat brain than homologous cationic nanocomplexes following CED administration [33] . Here we have focused on developing this formulation further, investigating the effects of PEGylation and an alternative targeting moiety, peptide Y. We relate the biophysical properties of these novel nanocomplexes to their transfection efficiencies in vitro and in vivo in rat brain, as well as brain distribution by MRI.
Anionic nanocomplex formulation protocols were first optimized in terms of method of mixing and molar charge ratios, then structural and functional studies were performed to compare the PEGylated formulations with non-PEGylated anionic and cationic formulations. The cationic LPD nanoparticles had a similar size to the anionic nonPEGylated PDL A . The anionic PEGylated nanoparticles were slightly larger in diameter than non-PEGylated anionic formulations, while their charge was less anionic due probably to PEG shielding. TEM images of anionic nanoparticles showed that there were no significant differences in morphology between the different PEGylated and non-PEGylated anionic formulations and cationic LPD formulations reported previously [34] .
DNA packaging was significantly less efficient in anionic PDL A formulations than in cationic LPD although PEGylation improved it to 80% from 65% in the non-PEGylated anionic formulation, which matched that of the cationic LPD formulation with approximately 85% efficiency. We then tested nanoparticle stability using mouse serum at 50% concentration (v/v) which approximates in vivo conditions [46] . PEGylated and non-PEGylated PDL A formulations were far more stable in serum than cationic nanocomplexes which aggregated due to their interactions with anionic serum proteins [59] . Aggregation of cationic liposomes leads to reduced bioavailability, increased toxicity, reduced binding to cells and clearance in vivo of cationic nanoparticles by the reticuloendothelial system (RES) [46, 60] and so we anticipate improved properties for anionic nanoparticles administered systemically. While extracellular stability is an essential requirement for an efficient nucleic acid delivery formulation, effective transfection is also influenced by the ease of release of the cargo within the cell [36] . The cationic LPD formulation dissociated more easily and to a greater extent after treatment with heparin than PDL [61] . In addition, PEGlipids with the shortest acyl chain, provided the least liposome protection with rapid elimination of the liposomes from the circulation within 1 h after liposome injection [62] . The different sensitivities of PEGylated and non-PEGylated anionic nanocomplexes to heparin, may be explained by the greater anionic charge of the latter increasing resistance to dissociation. Toxicity assays showed that there was no difference between the PEGylated and non-PEGylated anionic formulations although there was some evidence of toxicity for the cationic formulations consistent with previous studies comparing anionic and cationic formulations [21, 22, 24] .
We then compared the transfection efficiencies of the anionic formulations in different cell lines using different peptides, targeting (peptide Y) and non-targeting (peptides PS and K 16 16 in all cell lines examined, suggesting receptorspecific transfection. The receptor for peptide Y is unknown and so to evaluate receptor-mediated transfection specificity, cells were incubated with the competing peptide ligand, YL, before transfecting with peptide Y-containing nanocomplexes. This led to reduced transfection of both peptide Y-targeted anionic and cationic nanocomplexes, although the degree of inhibition of transfection was much greater with the anionic formulation. The scrambled control peptide, YSL, had no effect on transfection in targeted formulations, while transfections of cells containing non-targeting peptide PS were not affected by either YL or YSL. These studies support the hypothesis that anionic nanocomplexes transfect by receptor-specific pathways, while cationics transfect by charge-mediated non-specific routes, which can be enhanced by a targeting peptide ligand.
In relating differences in transfection efficiency to biophysical properties, PDL A , the least effective transfection agent, possessed the highest anionic charge and was the least efficient formulation for both DNA packaging and release, although its high anionic charge was associated with significantly higher specificity for ligand-mediated transfection than that of cationic LPD. The high anionic surface charge would reduce cell surface interactions and endocytosis and this, combined with the poor DNA release kinetics help to explain the poor transfection efficiency compared to the cationic LPD. The improved transfection efficiency of PEGylated anionic formulations was associated with improved dynamic properties of the nanocomplexes in that they both packaged and released DNA more effectively than the non-PEGylated formulation and had lower anionic surface charge. In fact the optimal PEGylated formulation PDL AP 2 was a better transfection agent than even the cationic LPD, displaying a much higher degree of receptor-mediated transfection than cationic formulations. Of the two PEGylated formulations PDL AP 2 was slightly more stable to heparin-mediated dissociation than PDL AP 1 but otherwise presented with similar biophysical properties of size, charge and morphology. Thus PDL AP 2 may better retain its structural integrity during the transfection process in the anionic environment of the cell surface while retaining greater dynamic properties for DNA release within the cell, and hence achieve the greater transfection efficiencies observed.
We then investigated an in vivo application involving direct injection of nanoparticles to the brain by CED where anionic formulations offer the promise, of more widespread dispersal of nanoparticles from a single administration as they are less likely to adhere to cells non-specifically than similarly sized cationic nanoparticles [33, 43] , while other studies suggested that surface modification by PEGylation further enhanced distribution of anionic [63] but not of cationic nanoparticles [56, 63] . In this study, nanocomplex formulations were labeled with gadolinium and rhodamine to enable detection by MRI and fluorescence microscopy, respectively [33] . Formulations compared for dispersal within the brain and transfection included, i) an anionic PDL AP 2-based formulation, Ani PDL APRG ,
ii) a cationic formulation, Cat PDL APRG , containing the same anionic liposome as PDL AP 2 but formulated with a lower amount of the anionic liposome (DOPG/DOPE) to make cationic nanocomplexes, and iii) a second cationic nanocomplex, Cat L CPRG PD, prepared with cationic liposomes. The distribution of the anionic formulation by MRI was greater than either cationic formulation in both striatum and corpus callosum. The difference in distribution between the Cat L CPRG PD and Cat PDL APRG , may be attributed to the higher positive charge (+ 57.0 and + 16.9 mV, respectively) ( Table 1) leading to an increase in non-specific binding close to the cannula tip [63] . Distribution for all formulations was greater in the corpus callosum infusions due to the more compact nature of the striatum and the consequent importance of size limitations on distribution. The qRT-PCR analysis confirmed that GFP transgene expression was achieved in two regions of the brain (corpus callosum and striatum). All formulations achieved transgene expression in both brain areas with no statistical differences among the different groups. The higher local concentration of the cationic formulation may provide an advantage for transfection near the injection site compared to the anionic formulations, which are better dispersed but more diluted, reducing their local transfection efficiency. Future studies will be required to investigate optimal dosage for anionic formulations. The potential for efficient, targeted gene expression from anionic nanocomplexes combined with their improved distribution by CED suggests their utility for delivery of therapeutic genes to the brain.
Conclusions
In this study we describe a novel, multifunctional, anionic nanocomplex and demonstrated that optimized PEGylation strategies enhanced transfection efficiency and receptor-targeted specificity, possibly by lowering repulsion forces from the anionic moieties on the cell surfaces. This contrasts with cationic synthetic nanocomplex formulations where PEGylation typically reduces transfection efficiency. Distribution of gadolinium-labeled nanocomplex formulations in brain, administered by direct delivery, was improved in anionic formulations with levels of transfection equivalent to cationic formulations, demonstrating the potential for theranostic delivery of genes and contrast agents to allow monitoring of biodistribution by MRI.
Supplementary data to this article can be found online at http://dx. doi.org/10.1016/j.jconrel.2013.11.014.
